NEW LABORATORY ANIMAL FACILITY IN CHINA

[Guest guest]

[image: Powered by Business Wire] <http://home.businesswire.com/>

*Search Results for Google*

http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view & ne\

wsId=20051127005034 & newsLang=en

[image:

http://www.bridgepharmaceuticals.com/]

<http://www.bridgepharmaceuticals.com/> November 27, 2005 11:45 PM US

Eastern Timezone

 

*Bridge Pharmaceuticals Dedicates Its Preclinical Drug Development

Laboratory in Beijing*

 

BIOWIRE2K

SAN FRANCISCO--(BUSINESS WIRE)--Nov. 27, 2005--

 

Bridge Pharmaceuticals Inc., Together With WI Harper and Vital Bridge,

Announce the Dedication of Its State-of-the-Art Preclinical Drug Development

Laboratory at Zhongguancun Life Science Park in Beijing

 

 

Today, Bridge Pharmaceuticals had the dedication ceremony for its recently

completed Bridge Zhongguancun Preclinical Drug Development Laboratory I. In

attendance at the ceremony were: San Francisco Mayor Gavin Newsom; Deputy

Mayor Beijing Municipal Office Hao Lu; Beijing Deputy Mayor Bo-Yuan Fan; US

Embassy Senior Commercial Officer Craig Allen; Former Beijing Deputy Mayor

Zhao-Guang Hu; Director of Beijing Municipal Industrial Development Bureau

Lian-Yuan Cheng; Director of Beijing Municipal Science Technology Office Hai

Feng; and Former San Francisco Mayor Frank Jordon.

 

This 7,800 square meter facility puts Bridge at the forefront of preclinical

outsourcing to China and will be the first and only US level GLP and AAALAC

designed facility in China. The Zhongguancun facility will house primates,

rodents, canines, rabbits. Services will include: FDA compliant GLP

toxicology, pharmacology, predictive PK/ADMET, safety pharmacology,

formulation and other services. Through its Vital Bridge joint venture,

Bridge has expert local partners in China that provide animal supplies from

the largest and only US-franchised (Charles River and Marshall Farms)

quality animal breeding facilities in China.

 

For Bridge, the opening of this facility marks the next phase in outsourcing

preclinical drug development to Asia. By controlling its own facility in

China, Bridge will have the capacity and expertise to provide FDA compliant

preclinical drug development services to pharmaceutical and biotech

companies throughout the world. This new facility positions Bridge as the

leading preclinical CRO in China targeting US and EU biopharmaceutical

companies.

 

" The San Francisco Bay Area is the birthplace of biotech and has remained

the worldwide leader in life sciences innovation. Escalation of the price of

drugs, as evidenced by California's recent ballot initiative, is an

increasing hardship and concern, " said San Francisco Mayor Gavin Newsom. " By

combining the technical resources and innovation of both the San Francisco

Bay Area and Beijing's life sciences community, this state-of-the-art

facility represents the next wave of global cooperation and evolution of

life sciences development. Bridge, and companies like Bridge, will allow San

Francisco to remain competitive in the life sciences, and cost effectively

develop more drugs, for smaller markets, in the new era of personalized

molecular medicine. We are pleased to see that a Bay Area company, Bridge

Pharmaceuticals, is taking the lead in this exciting global evolution of the

very best of the east and west. "

 

Founded in 2004, Bridge Pharmaceuticals, Inc. was spun-out of SRI

International (formerly Stanford Research Institute) to develop preclinical

service and drug development capabilities through leverage of the Asian

market. To date, Bridge has been subcontracting work through laboratories in

China and Taiwan (Beijing, Shanghai, Chengdu, Taipei and elsewhere). Bridge

is the first company to successfully use all China preclinical and CMC data

for successful filing of IND's with the US FDA and did so twice this year.

 

" Two years ago, we asked a simple question -- why can't one perform FDA

compliant drug development in China for US clients at a fraction of the

normal price? " CEO and President, Glenn Rice, Ph.D. said. " China has the

world's leading primate animal supply, highly qualified technical staff,

good English language skills and excellent worker productivity, in addition

to significant cost savings. Bridge builds on China's strengths by adding:

SOP sourcing from the US, world class facilities in the leading life

sciences park in China, FDA compliance, AAALAC level animal welfare, real

time data monitoring, combined with a US headquartered company that

envisions flexible partnerships.

 

" Of course doing business in China takes a lot of local know how,

experienced investment strategy and government support. We are combining the

best of east and west and we are confident it is going to revolutionize

preclinical drug development worldwide. We are indebted to our investors,

particularly Peter Liu, Chairman of the WI Harper Group who has guided our

business from day one in China. "

 

About Bridge Pharmaceuticals

 

Bridge Pharmaceuticals is a US-headquartered, SRI International spin-off

company focused on providing cost effective, FDA compliant drug development

services in Asia for US, EU and Asian based clients. Bridge has also formed

BridgeNet, an unprecedented network of pre-screened chemical and

manufacturing service providers in China and Taiwan, which provides western

clients with a single point of contact to access highly qualified and cost

effective drug development services in Asia. Bridge provides complete

end-to-end drug development expertise including US IND submissions. Bridge

focuses its development work in Taiwan and China. For more information,

visit www.BridgePharmaceuticals.com

<http://www.bridgepharmaceuticals.com/>or call 650-859-3853.

 

Copyright © 2005, Bridge Pharmaceuticals, Inc. All rights reserved.

Contacts Bridge Pharmaceuticals

Paul Joyce, 650-859-4504

pjoyce [image: Print this

Release]<javascript:print()> Print

this Release <javascript:print()>

------------------------------

Terms of

Use<http://home.businesswire.com/portal/site/home/index.jsp?epi-content=REDIRECT\

& epi-process=process_redirect.jsp & mtitle=Terms+of+Use>

| ©

Business Wire

2005<http://home.businesswire.com/portal/site/home/index.jsp?epi-content=REDIREC\

T & epi-process=process_redirect.jsp & mtitle=Copyright>

------------------------------